Immunogen (IMGN)

Company Profile

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days.

Company profile

Ticker

IMGN

Exchange

NASDAQ

Website

www.immunogen.com

CEO

Mark Enyedy

Incorporated

Massachusetts

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Abbott Laboratories • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

IMMUNOGEN INC

SEC CIK

0000855654

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Hurricane, LLC • ImmunoGen US Holding, Inc. • ImmunoGen Europe Limited • ImmunoGen Switzerland GmbH • ImmunoGen BioPharma (Ireland) Limited • ImmunoGen Securities Corp. ...

IRS number

42726691

IMGN stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

8-K

Entry into a Material Definitive Agreement

5 May 23

424B5

Prospectus supplement for primary offering

5 May 23

424B5

Prospectus supplement for primary offering

3 May 23

8-K

ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer

3 May 23

8-K

Entry into a Material Definitive Agreement

2 May 23

S-8

Registration of securities for employees

28 Apr 23

S-8

Registration of securities for employees

28 Apr 23

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results

28 Apr 23

ARS

2022 FY

Annual report to shareholders

26 Apr 23

Transcripts

View all

IMGN

Earnings call transcript

2023 Q1

28 Apr 23

IMGN

Earnings call transcript

2022 Q4

1 Mar 23

IMGN

Earnings call transcript

2022 Q3

4 Nov 22

IMGN

Earnings call transcript

2022 Q2

29 Jul 22

IMGN

Earnings call transcript

2022 Q1

6 May 22

IMGN

Earnings call transcript

2021 Q4

25 Feb 22

IMGN

Earnings call transcript

2021 Q3

29 Oct 21

IMGN

Earnings call transcript

2021 Q2

30 Jul 21

IMGN

Earnings call transcript

2021 Q1

10 May 21

IMGN

Earnings call transcript

2020 Q4

12 Feb 21

Latest ownership filings

View all

144

Notice of proposed sale of securities

RA CAPITAL MANAGEMENT, L.P.

Financial summary

Financial statements Chart IMGN financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	201.25 mm	201.25 mm	201.25 mm	201.25 mm	201.25 mm	201.25 mm
Cash burn (monthly)	24.63 mm	19.70 mm	14.13 mm	20.04 mm	24.57 mm	21.84 mm
Cash used (since last report)	52.02 mm	41.61 mm	29.84 mm	42.32 mm	51.90 mm	46.13 mm
Cash remaining	149.23 mm	159.64 mm	171.40 mm	158.93 mm	149.35 mm	155.12 mm
Runway (months of cash)	6.1	8.1	12.1	7.9	6.1	7.1

Beta Read what these cash burn values mean

Financial data from Immunogen earnings reports.

Institutional ownership, Q1 2023

IMGN institutional ownership history Ownership history

93.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	189	202	-6.4%
Opened positions	23	31	-25.8%
Closed positions	36	46	-21.7%
Increased positions	59	67	-11.9%
Reduced positions	57	69	-17.4%

13F shares	Current	Prev Q	Change
Total value	775.69 bn	988.10 bn	-21.5%
Total shares	211.86 mm	210.10 mm	+0.8%
Total puts	1.41 mm	714.60 k	+97.8%
Total calls	4.15 mm	1.13 mm	+266.3%
Total put/call ratio	0.3	0.6	-46.0%

Largest owners	Shares	Value	Change
Ra Capital Management	21.85 mm	$83.92 bn	0.0%
BLK Blackrock	18.00 mm	$69.11 bn	-0.1%
Adage Capital Partners GP, L.L.C.	17.63 mm	$67.71 bn	+58.6%
STT State Street	17.08 mm	$65.58 bn	-2.5%
JHG Janus Henderson	16.45 mm	$63.19 bn	+422.6%
Vanguard	14.97 mm	$57.48 bn	+4.1%
Wellington Management	9.86 mm	$37.88 bn	+6.9%
Redmile	8.05 mm	$30.90 bn	-5.7%
Maverick Capital	7.86 mm	$30.17 bn	+14.2%
MS Morgan Stanley	7.32 mm	$28.11 bn	+72.0%

Largest transactions	Shares	Bought/sold	Change
JHG Janus Henderson	16.45 mm	+13.30 mm	+422.6%
Jennison Associates	2.31 mm	-6.83 mm	-74.7%
Adage Capital Partners GP, L.L.C.	17.63 mm	+6.51 mm	+58.6%
Deerfield Management	0.00	-6.36 mm	EXIT
Woodline Partners	0.00	-5.03 mm	EXIT
Braidwell	0.00	-3.47 mm	EXIT
Artisan Partners Limited Partnership	3.18 mm	+3.18 mm	NEW
MS Morgan Stanley	7.32 mm	+3.06 mm	+72.0%
Nuveen Asset Management	3.19 mm	+1.91 mm	+147.9%
Granahan Investment Management	864.77 k	-1.32 mm	-60.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IMGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Apr 23	Isabel Kalofonos	RSU Common Stock	Grant	Acquire A	No	No	0	47,375	0.00	47,375
28 Apr 23	Isabel Kalofonos	Stock Option Common Stock	Grant	Acquire A	No	No	5.39	284,250	1.53 mm	284,250
31 Mar 23	Arbuckle Stuart A	Common Stock	Grant	Acquire A	No	No	3.84	3,417	13.12 k	3,417
31 Mar 23	Goldberg Mark Alan	Common Stock	Grant	Acquire A	No	No	3.84	4,394	16.87 k	58,194
31 Mar 23	Thackray Helen M.	Common Stock	Grant	Acquire A	No	No	3.84	1,953	7.50 k	1,953